Tamas Masszi (Tamás Masszi)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 8

Top Venues

Cardiovascular diabetology

Leukemia & lymphoma

Biomarkers in medicine

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Semmelweis University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Semmelweis University Jun 01 2016

Hungary

Professor :: 3rd Department of Internal Medicine

Publications

Tara Cochrane, Alicia Enrico, Guillermo José Ruiz Argüelles, Evgueniy Hadjiev, Ewa Lech-Maranda, Tamas Masszi, Eugene A Nikitin, Tadeusz Robak, Robert Weinkove, Shang-Ju Wu, Beenish S Manzoor, Todd Busman, Madhavi Pai, Viktor Komlosi, Mary Ann Anderson
Updated quality of life data from the phase 3b VENICE II trial: patients with relapsed or refractory chronic lymphocytic leukemia receiving venetoclax monotherapy. Leukemia & lymphoma (2023)
Ákos Nádasdi, Viktor Gál, Tamas Masszi, Anikó Somogyi, Gábor Firneisz
PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content. Cardiovascular diabetology 22 (1) (2023)
Ákos Nádasdi, Viktor Gál, Tamas Masszi, Anikó Somogyi, Gábor Firneisz
PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content. Cardiovascular diabetology 22 (1) (2023)
Ákos Nádasdi, Viktor Gál, Tamas Masszi, Anikó Somogyi, Gábor Firneisz
PNPLA3 rs738409 risk genotype decouples TyG index from HOMA2-IR and intrahepatic lipid content. Cardiovascular diabetology 22 (1) (2023)
Ákos Nádasdi, György Sinkovits, Ilona Bobek, Botond Lakatos, Zsolt Förhécz, Zita Z Prohászka, Marienn Réti, Miklós Arató, Gellért Cseh, Tamas Masszi, Bela Merkely, Peter Ferdinandy, István Vályi-Nagy, Zoltán Proházka, Gábor Firneisz
Decreased circulating dipeptidyl peptidase-4 enzyme activity is prognostic for severe outcomes in COVID-19 inpatients. Biomarkers in medicine 16 (5) (2022)
Pieter Sonneveld, Asher Chanan-Khan, Katja Weisel, Ajay K Nooka, Tamas Masszi, Meral Beksac, Ivan Spicka, Vania Tietsche de Moraes Hungria, Markus Munder, Maria-Victoria Mateos-Manteca, Tomer M Mark, Mark-David Levin, Tahamtan Ahmadi, Xiang Qin, Wendy Garvin Mayo, Xue Gai, Jodi Carey, Robin Carson, Andrew Spencer
Overall Survival With Daratumumab, Bortezomib, and Dexamethasone in Previously Treated Multiple Myeloma (CASTOR): A Randomized, Open-Label, Phase III Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Jerald P Radich, Andreas Hochhaus, Tamas Masszi, Andrzej Hellmann, Jesper Stentoft, María Teresa Gómez Casares, J Valentín García-Gutiérrez, Eibhlin Conneally, Philipp D le Coutre, Norbert Gattermann, Bruno Martino, Susanne Saussele, Francis J Giles, David Morrall Ross, Paola Aimone, Sai Li, Ksenia Titorenko, Giuseppe Saglio
Treatment-free remission following frontline nilotinib in patients with chronic phase chronic myeloid leukemia: 5-year update of the ENESTfreedom trial. Leukemia 35 (5) (2021)
Attila Tordai, Andras Bors, Katalin Piroska Kiss, Katalin Balassa, Hajnalka Andrikovics, Arpad Batai, Aniko Szilvasi, Katalin Rajczy, Dora Inotai, Eva Torbagyi, Lilla Lengyel, Aniko Barta, Peter Remenyi, Tamas Masszi
Donor KIR2DS1 reduces the risk of transplant related mortality in HLA-C2 positive young recipients with hematological malignancies treated by myeloablative conditioning. PloS one 14 (6) (2019)

Tamas Masszi.css-eqlu8i{font-size:small;padding-left:4px;} (Tamás Masszi)

Publication Activity (10 Years)

Top Topics

Top Venues

Tamas Masszi (Tamás Masszi)